Thera-SAbDab

DACLIZUMAB

>   Structural Summary
TherapeuticDaclizumab
TargetIL2RA
Heavy ChainQVQLVQSGAEVKKPGSSVKVSCKASGYTFTSYRMHWVRQAPGQGLEWIGYINPSTGYTEYNQKFKDKATITADESTNTAYMELSSLRSEDTAVYYCARGGGVFDYWGQGTLVTVSS
Light ChainDIQMTQSPSTLSASVGDRVTITCSASSSISYMHWYQQKPGKAPKLLIYTTSNLASGVPARFSGSGSGTEFTLTISSLQPDDFATYYCHQRSTYPLTFGQGTKVEVK
100% seqID Fv Structure3nfp [Fvs: AB, HL], 3nfs [Fvs: HL]
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG1
Highest Clinical Trial (June '19)Approved
Estimated Status (June '19)Active
Recorded Developmental TechnologyGS Gene Expression System
INN Year Proposed1994
INN Year Recommended1998
Companies InvolvedAbbVie, Biogen, Dana-Farber Cancer Institute, National Cancer Institute (USA), PDL BioPharma
Conditions ApprovedRenal transplant rejection
Conditions ActiveMultiple sclerosis
Conditions DiscontinuedAsthma, Graft-versus-host disease, Haematological malignancies, Immune-mediated uveitis, Liver transplant rejection, Psoriasis, Tropical spastic paraparesis, Type 1 diabetes mellitus, Ulcerative colitis
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]